Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 4,0814,100 of 20,252 grants

Completed NON-SBIR/STTR RPGS
Landscape and characterization of promoter mutations driving triple-negative breast cancer
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2023 – 2025

PROJECT SUMMARY Triple-negative breast cancer (TNBC) is traditionally associated with fewer identified genetic changes than other subtypes, precluding therapies that target tumor-s...

$2.5M
USD
Completed OTHER RESEARCH-RELATED
The Helicase and Nucleic Acid-based Machines Conference: Structure, Mechanism, Regulation and Roles in Human Diseases
NATIONAL CANCER INSTITUTE Federation of Amer Soc for Exper Biology United States 2023 – 2024

Project Summary/Abstract The goal of this application is to obtain funding to support the biennial FASEB conference Helicases and Nucleic Acid-Based Machines: Structure, mechanism,...

$105K
USD
Active NON-SBIR/STTR RPGS
Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia
NATIONAL CANCER INSTITUTE Oregon Health & Science University United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT Kinase inhibitor therapy has made a minimal impact on the clinical treatment of patients with Acute Myeloid Leukemia (AML). We have shown that inhibition o...

$4.88M
USD
Active NON-SBIR/STTR RPGS
Intersection of autophagy and vesicle trafficking in Her2-positive breast cancer
NATIONAL CANCER INSTITUTE University of Cincinnati United States 2023 – 2028

Breast cancer is the most common malignancy among US women and remains a major health threat with high incidence and lethality due to therapeutic resistance and metastasis. Breast...

$3.87M
USD
Active NON-SBIR/STTR RPGS
An urinary drug disposing approach for treatment of bladder Cancer
NATIONAL CANCER INSTITUTE Weill Medical Coll of Cornell Univ United States 2023 – 2028

Project Summary Most bladder cancer (BC) patients are diagnosed at an early stage. More than 80% of cases are non-muscle invasive BC (NMIBC). The standard treatment involves removi...

$5.95M
USD
Completed NON-SBIR/STTR RPGS
Landscape and characterization of promoter mutations driving triple-negative breast cancer
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2023 – 2025

PROJECT SUMMARY Triple-negative breast cancer (TNBC) is traditionally associated with fewer identified genetic changes than other subtypes, precluding therapies that target tumor-s...

$1.88M
USD
Active NON-SBIR/STTR RPGS
Improving Understanding of Quality End of Life Care Using a Dyadic Approach
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2023 – 2028

Project Summary/Abstract There is strong national consensus about the need to deliver high-quality care at the end of life (EOL) for patients with advanced (distant metastasis) can...

$6.07M
USD
Active TRAINING, INDIVIDUAL
Investigating the role of melanoma-adipocyte cell junctions in heterotypic communication and tumor progression
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2023 – 2026

PROJECT SUMMARY Melanoma is the most lethal skin cancer. Few treatment options exist for patients with metastatic disease. Upon tumorigenesis, melanoma cells invade into dermal and...

$489.9K
USD
Active NON-SBIR/STTR RPGS
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2023 – 2028

Summary/Abstract While prostate-specific membrane antigen-targeted radiopharmaceutical therapy (PSMA-RPT) improves the survival of metastatic castration-resistant prostate cancer (...

$5.28M
USD
Active NON-SBIR/STTR RPGS
Developing novel therapy to improve outcomes in MCL
NATIONAL CANCER INSTITUTE Ohio State University United States 2023 – 2028

PROJECT SUMMARY Mantle cell lymphoma (MCL) is an incurable non-Hodgkin lymphoma, and despite intensive therapeutic approaches, the median progression-free survival after first-line...

$4.07M
USD
Active NON-SBIR/STTR RPGS
Integrating Multiple Electronic Health Records Systems to Improve Lung Cancer Outcomes
NATIONAL CANCER INSTITUTE Stanford University United States 2023 – 2028

Recent advances in screening and treatment have increased the number of lung cancer (LC) survivors (~571,340 LC survivors as of 2019). However, studies have shown that these surviv...

$6.59M
USD
Active NON-SBIR/STTR RPGS
Aging trajectories and outcomes of older adults with acute myeloid leukemia
NATIONAL CANCER INSTITUTE University of Nebraska Medical Center United States 2023 – 2028

PROJECT SUMMARY In the US, over one-third of older adults ≥60-years with acute myeloid leukemia (AML) die without receiving any chemotherapy, primarily due to concerns of cognitive...

$6.11M
USD
Active NON-SBIR/STTR RPGS
Re-engineering differential regulation of ferroptosis in melanoma microenvironment
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

Project Summary Melanoma is an aggressive and highly metastatic skin cancer. Although modern combination checkpoint inhibitors revolutionized clinical outcomes in advanced cases, o...

$6.91M
USD
Active NON-SBIR/STTR RPGS
The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer Detection
NATIONAL CANCER INSTITUTE University of Miami School of Medicine United States 2023 – 2028

Screening for prostate cancer saves lives but results in an overwhelming number of men being subjected to unnecessary, invasive prostate biopsies, and the risk of over diagnosis an...

$5.2M
USD
Completed TRAINING, INDIVIDUAL
Role of Gastrokine 2 in pancreatic cancer development
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2023 – 2025

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest adult cancers with a 5-year survival rate of only 11% and is one of the top five leading causes of cancer-r...

$392.1K
USD
Active NON-SBIR/STTR RPGS
Targeting LKB1-null lung adenocarcinoma with innate immune system
NATIONAL CANCER INSTITUTE Emory University United States 2023 – 2028

Project Summary The tumor suppressor LKB1 is one of the most frequently mutated genes in lung adenocarcinoma (LUAD). This tumor subgroup is resistant to immune checkpoint blockade...

$4.31M
USD
Completed TRAINING, INDIVIDUAL
Role of Gastrokine 2 in pancreatic cancer development
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2023 – 2025

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest adult cancers with a 5-year survival rate of only 11% and is one of the top five leading causes of cancer-r...

$404.9K
USD
Active NON-SBIR/STTR RPGS
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2023 – 2028

Summary/Abstract While prostate-specific membrane antigen-targeted radiopharmaceutical therapy (PSMA-RPT) improves the survival of metastatic castration-resistant prostate cancer (...

$5.67M
USD
Active NON-SBIR/STTR RPGS
Re-engineering differential regulation of ferroptosis in melanoma microenvironment
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

Project Summary Melanoma is an aggressive and highly metastatic skin cancer. Although modern combination checkpoint inhibitors revolutionized clinical outcomes in advanced cases, o...

$6.42M
USD
Active NON-SBIR/STTR RPGS
Integrating Multiple Electronic Health Records Systems to Improve Lung Cancer Outcomes
NATIONAL CANCER INSTITUTE Stanford University United States 2023 – 2028

Recent advances in screening and treatment have increased the number of lung cancer (LC) survivors (~571,340 LC survivors as of 2019). However, studies have shown that these surviv...

$6.12M
USD